The poor outcomes in esophageal adenocarcinoma (EAC) prompted us to interrogate the pattern and timing of metastatic spread. Whole-genome sequencing and phylogenetic analysis of 388 samples across 18 individuals with EAC showed, in 90% of patients, that multiple subclones from the primary tumor spread very rapidly from the primary site to form multiple metastases, including lymph nodes and distant tissues-a mode of dissemination that we term 'clonal diaspora'. Metastatic subclones at autopsy were present in tissue and blood samples from earlier time points. These findings have implications for our understanding and clinical evaluation of EAC.
M etastatic spread to distant sites accounts for the majority of cancer deaths 1 . Understanding the anatomical extent of disease is essential to determine the optimum treatment strategy. This is challenging since cancer continually evolves at a microscopic scale, often beyond the resolution of clinical imaging techniques. Furthermore, the patterns of metastatic spread are often unpredictable in terms of time course and anatomical location. Treatments may therefore be unnecessarily toxic (for example, radical lymphadenectomy and chemotherapy) or insufficiently aggressive, leading to high recurrence rates [2] [3] [4] .
Esophageal cancer is the sixth most common cause of cancerrelated death worldwide and the current median survival time is still less than 1 year (ref. 5 ). Incidence rates for esophageal adenocarcinoma (EAC) have risen sharply and it is now the predominant subtype in developed countries. Prognosis is highly variable for patients with EAC, as shown by the wide range of 5-year survival (18-47% with lymph node involvement), making it difficult to advise patients embarking on a long course of grueling treatment 2, 6 .
Theoretical and experimental studies attempt to understand how tumor cell populations respond to selective pressures over time 7 . A number of models of tumor evolution have been proposed, including linear, branching, neutral and punctuated evolution, but the extent to which these are specific to a given cancer type or co-occur is controversial 8, 9 . Genome-sequencing studies have attempted to delineate different models of evolution 10 . However, many of these studies have focused solely on evolution within the primary site, and knowledge of how genetic diversity emerges during metastasis remains limited. The lack of understanding is in part due to the practical challenge of collecting multiple samples over space and time from patients with advanced-stage cancer.
To better understand the evolution of EAC, we designed a prospective study with extensive sampling over time, including samples from diagnosis and surgery, as well as at warm autopsy ( Fig. 1 ). We used whole-genome sequencing (WGS) at high depth (50×; to identify mutations) and at shallow coverage (1×; to track known variants), to interrogate the clonal architecture across time and space.
Results
Genomic architecture of 18 patients. A total of 18 patients were included in the study. The clinical demographics of these patients are shown in Supplementary Tables 1 and 2, with details of the individual samples given in Supplementary Tables 3 and 4 . In the first part of the study ( Fig. 1a and Extended Data Figs. 1 and 2), we used 50× WGS to construct a phylogenetic tree for each patient, to understand the relationship between the primary and metastatic tumors (Fig. 2 , Extended Data Fig. 3 , Supplementary Fig. 1 and Supplementary Tables 3 and 4 ). Mutation clustering was performed and the fractions of tumor cells carrying each set of mutations (cancer cell fractions (CCFs)) within each sample were used to determine: (1) the clonal and subclonal architecture of each tumor (subclonal CCF < 95%; clonal CCF > 95%); (2) the hierarchy of events; and (3) the distance of these subclonal or clonal clusters from the most recent common ancestor (MRCA) ( Fig. 1a and Extended Data Figs. 1 and 2) . The CCF and number of single-nucleotide variants (SNVs) associated with each clone and subclone are shown in Supplementary Tables 5 and 6 ; the tumor purity of each sample using the Battenberg algorithm 11 is shown in Supplementary  Table 7 ; and the confidence intervals of the clonal and subclonal CCFs are shown in Supplementary Table 8 . Detailed information on experimental design is provided in the Life Sciences Reporting Summary.
These analyses enabled us to construct phylogenetic trees (Methods). In all patients, we observed a long trunk compared with the rest of the tree (median: 19,034 SNVs; interquartile range (IQR): 11,299-63,908), consistent with previous studies in EAC 12, 13 . The median size of clonal or subclonal clusters across all patients was 3,069 SNVs (IQR: 1,332-63,908) and only two out of 157 contained fewer than 200 SNVs (S1_3 and P5_11) (Extended Data Fig. 3 and Supplementary Table 6 ).
The key driver events 14, 15 are depicted on each phylogenetic tree ( Fig. 2 and Extended Data Fig. 3 ). The events identified as most frequent in previous studies occurred in the trunks of the phylogenetic trees, consistent with their previous classification as drivers. TP53 was mutated in the trunk of 16 out of 18 patients, consistent with our knowledge of the disease 14, [16] [17] [18] [19] . Amplifications (gene names in red) were often truncal, but also observed on the branches of the phylogenetic tree, providing evidence of divergence during later evolutionary stages ( Fig. 2 and Extended Data Fig. 3 ). The majority of events in driver genes were copy number alterations (CNAs) rather than SNVs or indels ( Fig. 2 and Extended Data Fig. 3 ) 14, 19, 20 . There was no significant difference in the overall number of structural variants between primary and metastatic samples (P = 0.41, generalized linear model; Extended Data Fig. 4b ). However, a larger proportion of structural variants in metastatic samples were retrotranspositions of mobile elements than in the primary samples (P = 0.045; Extended Data Fig. 4c ). This contrasts with pancreatic cancer (where deletions and fold-back inversions are more common in metastases) and breast cancer (where tandem duplications dominate) 21 . Interestingly, the high rate of L1 transposon activity in EAC has recently been associated with high activity in the germline 22 . Our results suggest a further increase in L1 activity in metastatic EAC. Furthermore, the proportion of structural variants found uniquely in metastases or in primary sites was higher than that of SNVs ( Fig. 2 and Extended Data 4a), suggesting an increase in genomic instability in later stages of the disease. However, it cannot be ruled out that some structural variants have not been identified in every sample as a result of lower sensitivity in the detection of structural variants than SNVs. Across the 18 patients, eight mutational signatures were observed, consistent with previous studies [23] [24] [25] [26] (Fig. 3a) , with varying prevalence across the patients. None of the signatures that we observed in patients in our cohort who had oncologic therapy have been associated with treatment with alkylating antineoplastic agents 27 , platinum therapy 28 or radiation therapy 29 .
Early seeding of oligometastases. Ten of 18 patients (S3, S4, P1-4, P6, P8-10) had both nodal and solid organ metastases, allowing a direct comparison of the genomic architecture between different metastatic sites ( Fig. 2) .
In four of these ten patients, an isolated clone or subclone confined to one or two distant metastases (that is, an oligometastasis, depicted as a dashed black node on the first branch of the phylogenetic tree) shared the highest congruence to the MRCA (P1, P4, P10 and S3 in Fig. 2 , and subclones P1_2, P4_3, P10_2 and S3_2 in Supplementary Table 5 ). In P1, this clone (P1_2) was observed only in the primary tumor and a pleural metastasis. In S3 and P4, the clone involved in this isolated seeding was identified at a single distant site and not in the primary tumor (S3_2: liver metastasis (D1); P4_3: para-aortic lymph node (L3)). In P10, the early-seeding clone (P10_2) was shared between a distant para-aortic node and a subclonal metastasis in the right hemi-diaphragm. The subclones associated with these isolated seeding events showed little divergence from the MRCA across these four patients (median: 1,913 SNVs; range: 832-8,591 SNVs), suggesting early seeding to distant metastases. Notably, in P9, a subclone (P9_10; Supplementary Table 5 ) was found in a premalignant area of Barrett's esophagus and a pleural metastasis, but not in any of four areas of the primary tumor subject to 50× WGS. This subclone lineage shared no variants with the main lineage and appeared to be an independent second cancer ( Fig. 2) .
A single clone gives rise to multiple metastatic sites. A striking observation was that nine out of ten patients had a clone (outlined in red on the phylogenetic tree in Fig. 2 ) that was followed by dispersion of multiple subclones from the primary to discrete metastatic sites, resulting in a model of metastasis that we term 'clonal diaspora' . In most patients, this dispersion was visually stellate in nature, this being defined as a feature of a phylogenetic tree involving three or more branches leading from a single founder clone (see details in the Discussion). The subclones forming diasporas were located in both primary and metastatic tissue in eight patients (P1, P2, P3, S4, P4, P6, P8 and P10), and in P9 were unique to metastases ( Fig. 2) . The only two patients lacking a stellate pattern on the phylogenetic tree were P10 and S3. For S3, there was no autopsy and limited tissue sampling, and the early distant seeding in this patient is consistent with a pattern of parallel evolution (Fig. 2 ).
Subclonal spread is not constrained by location or tissue type.
In the second step of the study, we tracked the spread of metastases across a wider range of lymph node and distant tissue sites by performing 1× WGS in a further 248 tissue samples from six patients with autopsy ( Fig. 1a ,c). We did not call new mutations, as this would not be possible at 1× sequencing, but we used this method to detect the spread of clones and subclones previously identified using 50× WGS (bioinformatic validation of the methods is provided in Extended Data Figs. 5 and 6 and the Supplementary Note, while wet lab validation is shown in Extended Data Fig. 7 and Supplementary Table 9 ). The samples used in this part of the study are outlined in Supplementary Table 10 . The median size of subclonal and clonal clusters (identified previously at 50× WGS) that we aimed to detect using 1× WGS was 3,784 (IQR: 1,966-49,955). Sample sites were grouped according to their similarity, based on the presence of subclones and clones previously detected with 50× WGS (Supplementary Note). The resulting groups of samples are color coded and numbered, and each sample site, colored by group, is shown on the adjacent body map ( Fig. 4 ; see also Supplementary Note). Notably, the samples that grouped together based on shared clonal origins were widely dispersed anatomically.
Four out of six patients with extensive spatial sampling ( Fig. 4 ) had liver metastases evaluated, and three of these contained samples that were more similar to local lymph node metastases than neighboring liver metastases (P4, P6, P8, but not P10). The high number of groups within the liver (up to four) suggested seeding by multiple subclones (seen in P4, P6 and P8), whereas the single group in the liver of P10 (orange; group 3) indicated seeding by a common progenitor or a set of closely related cells.
A comparison of lymph node location and genomic contiguity showed no evidence of tropism (that is, genomically similar lymph nodes did not occupy nearby anatomical locations). Lymph nodes above and below the diaphragm were frequently seeded from common events (P2: groups 1 and 3; P4: groups 5 and 6; P6: group 5; P8: groups 2, 3, 5 and 6; P10: group 4), at odds with a progression from local to distant nodes. Similarly, a comparison of lymph node and solid organ metastases showed scant evidence for tropism, with the exception of P1 (Supplementary Note). This patient underwent surgical resection and subsequently had metastatic disease recurrence. In this cancer, separate subclones seeded lymph node and pleural metastases (Figs. 2 and 4). Notably, the distant metastasis (D1) was an early branching oligometastasis, whereas the lymph nodes (L1 and L2) constituted the later diaspora event (black and red circles, respectively, in Fig. 2 ).
We further traced regions of the primary tumor at autopsy that had similar subclonal compositions to each of the metastases, shown as adjacent tumor maps ( Fig. 4 , bottom left of each patient). Subclones occupied spatially distinct areas in the primary tumor. Supplementary Tables 3 and 4 ). An organ is shown in color if metastases were sequenced from that site. The adjacent wedged semicircle depicts the clinical timeline for each patient. Each wedge corresponds to 1 month. Blue wedges indicate the total lifetime of the patient, while red wedges show periods of therapy. Phylogenetic trees for each patient are shown to the right (see the Supplementary Note and Extended Data Figs. 1 and 2 for the methodology). Pink, purple and yellow represent, respectively, truncal events shared by all samples, branch events shared by more than one sample, and leaf events unique to a sample. The circle at the end of a trunk, branch or leaf represents a clone or subclone. Each clone or subclone is annotated to show which samples it was present in (E1-E4: primary esophageal tumor; E* and E** refer to historical endoscopic samples; L1-L4: lymph nodes; D1-D8: distant metastases; B: Barrett's esophagus). For example, the label 'E1,L2' indicates that this subclone was seen only in samples E1 and L2. The CCF of each subclone/clone (barring the MRCA) is provided in Supplementary Tables 5 and 6. The lengths of the tree branches are reflective of the number of SNVs in the subclone/clone. The scales in the top right corner are relative, given the variable numbers of SNVs per patient. Trees are annotated with potential driver events (black: missense variants; red: amplifications). Gray dots with a black, dashed outline denote the first subclone/clone to metastasize that would be classified as noncurative based on its anatomical location. Red dots mark the founder clone of a diaspora on the phylogenetic tree. since there may be non-copy number drivers present in additional patients. The ratio of nonsynonymous to synonymous SNVs (dN/dS) was analyzed across all patients in order to assess the We also looked for driver amplifications post-MRCA or postdiaspora on a per-patient basis, and identified selection in six out of ten patients. However, this is likely to be an underestimate, presence or absence of positive selection 30 . The results indicated positive selection in both clonal and subclonal genomes, albeit with lower levels of selection within subclones (Extended Data Fig. 8 ).
Metastatic spread is rapid in EAC.
To examine the timing and speed of metastatic spread, we analyzed base substitution mutational signatures, particularly the aging signature, which features a predominance of C>T transition in the NpCpG trinucleotide context (Figs. 1a and 3).
Signature 1 arises from the spontaneous or enzymatic deamination of methylated cytosines, which is an endogenous process that occurs continuously in both healthy and cancerous cells. This has been shown to act as a molecular clock 27, [31] [32] [33] [34] [35] , and was therefore used here as a method to examine the temporal relationship between metastases. Using a previously described method for deconvolving mutational signatures 35 , we observed that signature 1 was present in the trunk but absent in all subclones that constituted diaspora (following the red parental clone in Fig. 2 ) for P2, P4, P6, P9, P10 and S4, and it was significantly reduced for P1 (21 to 3%) and P3 (16 to 9%) (Wilcoxon signed-rank test, P = 0.039; Fig. 3c ). To account for the possibility that the number of signature 1 mutations in branch subclones was below the resolution of our deconvolution methods, we also identified the number of mutations with the characteristic feature of signature 1 (that is, C>T mutations in a CpG context). To estimate the time of appearance of diaspora, we compared the number of these characteristic mutations that occurred along the trunk to the parental red clone marking the onset of diaspora with those that occurred on the longest branch leading from this point. The median proportion of such mutations occurring before the onset of diaspora was 0.911 ( Fig. 3b ). Thus, in the majority of patients, one might deduce that little time has elapsed between the appearance of the cell that is ancestral to disseminating cells and the individual cells that seeded each of the metastases. With the exception of P8, the proportion of mutations attributed to signature 1 was significantly lower after the parental (red) clone on the phylogenetic tree (P < 9.1 × 10 −5 , chi-squared test across all patients; Fig. 3c ), suggesting an increase in the activity of other processes in later evolutionary stages ( Supplementary Table 11 ). Of note, there was an increase in the proportion of signature 3 in subclonal SNVs compared with clonal SNVs (Wilcoxon signed-rank test, P = 0.019; Fig. 3b ), suggesting that failure of DNA double-strand break repair is predominantly a late-stage event in EAC. Early detection from diagnostic samples. Next, we investigated eight patients (P1-4, P6 and P8-10) for which the esophageal diagnostic formalin-fixed, paraffin-embedded (FFPE) biopsy or surgical sample (primary tumor at resection for P1 and lymph node from surgery for P9) were available, with a median time before autopsy of 12 months (range: 5-30 months) ( Fig. 1) . The diagnostic sample for P1 was snap frozen and sequenced to 50× ( Fig. 2 ; highlighted with an asterisk in Extended Data Fig. 9 ), while 1× WGS was performed on the remainder of patients. Between 8 and 36% of the subclones and clones observed in samples taken from autopsy were also present in the diagnostic samples (Supplementary Note and Extended Data Fig. 9 ). In six patients, all subclones identified from the biopsy samples were also found in the primary samples from autopsy. Two diagnostic endoscopic samples from P4 also contained many of the mutations found in the lymph node L2 at autopsy, which had not been previously identified in the primary tumor at autopsy (Fig. 2 (subclone P4_17) and Supplementary Table 5 ). Similarly, the biopsy sample from P10 contained a substantial number of mutations from both the oligometastasis that seeded D2 and L4 (Supplementary Table 5 ; P10_2) and the lineage that later metastasized to multiple sites (Fig. 2) . Notably, P4 and P10 had shorter survival times after diagnosis than the remaining patients (5 and 4 months, respectively). . Highlighting of entire organs shows those that were sequenced (see Supplementary Table 9 ) for a full list of the sample sites included in this part of the study. For example, liver metastases were only seen in P4, P6, P8, P10, while P2 had lymph node metastases only (represented by colored dots). Clustering was performed based on the presence of subclones and clones already detected using 50× WGS, and distinct clusters were identified for each patient, as shown by the legend (each group is both colored and numbered). Samples are displayed on the adjoining body maps, for which the color coding corresponds to the genomic clustering in the adjacent heat map. Sites with multiple samples are magnified and the division of samples is shown. Maps of the primary tumor (gray, below the heat maps), with representation of the metastatic subclones, are shown for each patient, with the colors of the subclones matching those in the matrix and body map. Areas shaded red in the primary tumor represent subclones that were not detected in the metastatic samples that underwent 1× WGS and were instead confined to areas of the primary tumor.
Plasma sample analysis at autopsy and earlier time points. We assessed the clonal composition of circulating tumor DNA (ctDNA) at earlier time points in seven blood samples from five patients ( Figs. 1 and 5a ,c, Extended Data Fig. 10 and Supplementary  Table 12 ). Combined 1× WGS subclone/clone detection, copy number aberrations and TP53 fractions using digital PCR data are displayed for two of these patients (P6 and P10) in Fig. 5a . Notably, P6 was a patient being treated with curative intent who had no radiological evidence of distant nodal or organ metastases at the time of clinical staging. However, at the time of diagnosis, mutations from the truncal cluster and three subclonal clusters later found in the metastases were already present in the plasma (Fig. 5a ), along with amplifications in MYC and GATA4. Patient S4 is noteworthy, as the brain metastases (D1 and D2 in Fig. 2 ) appeared to have originated from a subclone shared between the primary and a local lymph node, both of which were removed at the time of surgery (Extended Data Fig. 10c ). However, mutations from the truncal cluster and four subclonal clusters were already present in ctDNA before radiological recurrence.
In eight patients, plasma was available from rapid autopsy. One patient (P3) failed wet lab SNV validation and was hence removed from the SNV subclone analysis (Supplementary Note). Analysis of ctDNA showed that in all patients the truncal cluster from autopsy was also represented in plasma (Fig. 5c ). In addition, mutations from between zero and seven subclonal clusters were identified from plasma (Fig. 5c ). The ratio of mutations detected from each subclone was very consistent between blood from earlier time points and autopsy (Pearson's r range: 0.851-0.994; maximum P = 8.9 × 10 −4 ), and in two of five patients the proportion of mutations detected was higher in the earlier sample, suggesting an opportunity for earlier detection of heterogeneous cancer cell populations. Furthermore, subclonal proportions estimated from exome sequencing of plasma samples were highly correlated with those from 1× WGS (Supplementary Table 9 ).
The majority of driver CNAs identified in the MRCA of each tumor from 50× WGS of tissue samples were also identified in plasma, both at autopsy and at earlier time points (Fig. 5a,b) . In addition, MET amplification, which was not present in the MRCA in P1 (Fig. 2) , was identified in plasma both at autopsy and at an earlier time point (Extended Data Fig. 10a ), suggesting opportunities for early detection of metastatic subclones. Notably, however, amplifications found only in oligometastases or in post-diaspora subclones from 50× sequencing were not identified in plasma, despite many of them being detected in 1× sequencing of tissue samples (Fig. 5b) . A plausible explanation for this observation is that each of the many metastasizing subclones contributed insufficient material to the sum of detected ctDNA to enable confident detection of CNAs.
Discussion
We have gathered multiple lines of evidence suggesting that, for the majority of EACs, a complex mode of spread is operative. These lines of evidence can be summarized as follows (Fig. 6 ). We observe multiple subclones, each seeding multiple metastatic sites. These subclones are frequently derived from a single parental clone, generally resulting in a stellate pattern on the phylogenetic tree. Metastases in solid organs can bypass nodal involvement, and samples within solid organ sites frequently resemble distant metastases more closely than neighboring metastases within the same organ (that is, no tropism is observed). All metastases appear to have spread directly from the primary site, with little or no evidence of metastasis-to-metastasis seeding.
These features differ in some important respects from previously described models of metastasis and we propose that they may constitute a distinct, additional model of evolution. We suggest that this pattern be referred to as a 'diaspora' , by extension of the anthropological term to cancer 36 . Within this context, it is associated with the observation that multiple cell populations in metastatic sites are directly linked to the primary site of origin and that individual subclones seed multiple tissue types, analogous to a diaspora crossing multiple national boundaries.
A number of features were frequently associated with this phenomenon ( Fig. 6) , with nine of the patients (all except S3) displaying at least two of the four following features: (1) a stellate pattern on the phylogenetic tree, defined as three or more subclones emerging from the founder clones; (2) a lack of signature 1 mutations post-MRCA or post-diaspora; (3) spread of subclones to multiple organs of different types; and (4) evidence for selection in post-diaspora genotypes.
Until recently, the genomic architectures of metastatic samples have not been defined with enough resolution to discern temporal or spatial patterns of metastatic spread. Several distinct patterns are now emerging that are not necessarily mutually exclusive or cancer type specific. In pancreatic cancer, Yachida et al. 24 demonstrated that distant organ seeding was a late event consistent with a linear progression model. In prostate cancer, linear progression is often succeeded by multiple waves of seeding 37 . The same study further showed widespread subclonal evolution in metastases and metastasis-to-metastasis spread, in keeping with the relatively long longevity of prostate cancer. Strikingly, a stellate pattern was not observed in any of the patients in that study, despite using a similar design to that used here.
In Supplementary Table 13 , we compare the features of our proposed diaspora model with the previously posited linear 38 and parallel 8 models. Whereas the linear model predicts that a single subclone-seeded lymph node site is followed by transmission to distant organs, the diaspora model posits simultaneous seeding of multiple sites directly from the primary site. Unlike the parallel model, the diaspora model implies that metastasis formation occurs after the majority of evolution has occurred in the primary tumor, resulting in multiple subclones found in common between primary and metastatic tumors. Lymphatic and distant metastases in colon cancer have been shown to arise from independent subclones in the primary tumor with disparate evolutionary trajectories 39 . In contrast, in EAC, we find that individual subclones frequently seed both lymph node and distant organs, suggesting that disparate trajectories for nodal and solid organ metastases do not exist for this disease (Figs. 2 and 3 ). Of note we acknowledge that, despite the extensive and systematic sampling across all patients with autopsy, further sampling may add further branches to our phylogenetic tree, although this is unlikely to affect the diaspora event itself.
In common with the Big Bang model proposed for colorectal cancer 40 , our model predicts the occurrence of highly branching phylogenies. However, the Big Bang model proposes neutral dynamics, whereas we observe strong evidence for selection in subclonal populations in the form of dN/dS ratios and the occurrence of subclonal driver amplifications (Fig. 2, Extended Data Fig. 8 and Supplementary Fig. 2) . Moreover, the clonal maps of the primary tumor show subclones that occupy spatially discrete areas of the primary tumor ( Fig. 4) , in contrast with the intermixed subclones predicted by the Big Bang model 40 .
The sequence of events in metastatic progression may have clinical implications that require further study ( Supplementary  Table 13 ). Clonal architecture in EAC defies the anatomical location of lymph node stations and distant sites, which is the current basis for TNM staging and determines whether curative therapy is appropriate. It has been suggested that the high recurrence rate (52% within 1 year) results from seeding of distant metastases that are not detected at the time of diagnosis 26 . This study provides molecular evidence for this observation and highlights the need for different systemic approaches to disease management, including consideration of more aggressive adjuvant therapy, which is not currently the mainstay of treatment [41] [42] [43] [44] . With advances in the sensitivity of ctDNA assays, metastatic subclones may be detectable in the blood, helping to determine when systemic therapy is required post-surgery, and helping to detect the heterogeneity of acquired resistance 45 . Copy number variation in plasma may also be a future early-detection strategy 46 .
The occurrence of metastasis is a pivotal event in the life history of a cancer. Understanding the drivers behind such an event would have potential relevance to patient stratification and the prediction and prevention of metastatic spread 47 . While we have identified many drivers on the trunks of the trees before diaspora (Fig. 2) , we cannot be certain which event, if any, was the immediate trigger of diaspora in individual patients. In a number of patients, diaspora was coincident with an increase in the proportion of signature 3 mutations, associated with failure of DNA double-strand break repair by homologous recombination (Fig. 3b ). Our findings are in keeping with the failure of DNA repair driving the appearance of genomic heterogeneity. Whether the heterogeneity observed is itself the driver of diaspora or merely a symptom is an important area for future study. Our investigations of the potential drivers of diaspora were limited to genomic factors, and further multi-platform studies looking at epigenetic and transcriptomic factors are other important avenues of future research. We anticipate that analyses of single cells or small clusters from primary sites, disseminated tumor cells and circulating tumor cells will also yield finer resolution of the processes of dissemination and metastasis.
In cancer, there are currently very few in-depth studies examining the spatial and temporal evolution of metastases 48 . Further studies are required to ascertain the extent to which our diaspora theory pertains to other cancers.
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Methods
Statistics. Unless otherwise stated, statistical analyses were performed using R (version 3.3.3). Clustering of mutations was carried out using a previously published Bayesian Dirichlet process method, DPClust (https://github.com/ Wedge-Oxford/dpclust), which calculates CCFs of each SNV, taking into account tumor purity and copy number aberrations as previously described 49 . Analysis of structural variants used generalized linear models, implemented with the R package MASS. Grouping of 1× WGS samples was performed with the GENE-E package (https://software.broadinstitute.org/GENE-E/download.html). Wilcoxon signed-rank and chi-squared tests were used as described. Simulations were used to ascertain the robustness of DPClust to violations of the infinite sites assumption and its sensitivity to detect small deviations from stellate patterns. Simulations were also used to confirm the correlation between the number of mutations detected from 1× WGS and CCFs determined from 50× WGS, as described in the Methods, 'Shallow WGS for subclone identification' . dN/dS analysis was performed using the previously published package dndscv 50 (https://github.com/im3sanger/dndscv).
Patient recruitment and sample collection.
Patients with EAC were recruited from Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust with the explicit aim of studying the clonal evolution of metastases as a substudy within the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study. When it was clear that extensive sampling of metastases could not be achieved without multiple invasive procedures, the 'Phylogenetics of Oesophageal Neoplasia: an Investigation of Clonal Expansion' (PHOENIX) autopsy study was set up (under REC 07/H0305/52 and REC EE/0043) with a prospective study design. Due diligence was undertaken to ensure compliance with ethical regulations at all times. Patients were eligible if they were at least 18 years of age and had received a confirmed diagnosis of EAC following central pathology review. Patients were only approached for the PHOENIX study following a palliative diagnosis of metastatic EAC, with full involvement of the multidisciplinary team. Samples from the PHOENIX autopsy study were obtained within 6 h of death and all postmortems were carried out at Papworth Hospital NHS Foundation Trust, United Kingdom.
Samples from patients in the Cambridge OCCAMS study were obtained during diagnostic esophagogastroduodenoscopy, at endoscopic ultrasound and/or from the surgical resection specimen. Where possible, multiple samples were taken from spatially distinct sites of the primary tumor or metastases. In two patients, brain metastases were sampled at a clinically indicated craniotomy. Blood or normal squamous esophageal samples, at least 5 cm distant from the tumor, were used as a germline reference.
All tissue samples were snap frozen in liquid nitrogen immediately after collection and stored at −80 °C. Cancer samples were deemed suitable for DNA extraction only after consensus review of a hematoxylin and eosin-stained frozen section, from the same sample that would be sent for sequencing, by two expert pathologists who confirmed tumor cellularity at ≥70%.
Samples with ≥70% cellularity overall underwent dissection of the whole surface area with a scalpel, whereas marked areas of <70% underwent macrodissection or laser-capture microdissection aided by methylene blue staining visualized with a Zeiss PALM microscope. A hematoxylin and eosin-stained slide was obtained before and after extraction to confirm tumor cellularity of the microdissected section.
DNA was extracted from frozen tissues using an AllPrep DNA/RNA Mini Kit (Qiagen), and from blood samples using a Nucleon Genomic Extraction kit (Gen-Probe) according to the manufacturer's instructions. Some samples were preserved in paraffin blocks after initially being stored in formalin. DNA from these samples was extracted using a QIAamp FFPE Kit (Qiagen). Plasma extraction (for ctDNA) was performed using a QIAsymphony platform (Qiagen), per the manufacturer's instructions. All samples were eluted in 60 μl AE buffer and quantified using a High Sensitivity Qubit (Thermo Fisher Scientific).
We included 388 samples, predominantly from PHOENIX, and some additional samples from surgery and endoscopy (part of the International Cancer Genome Consortium (ICGC)).
All samples were collected according to a strict standard operating procedure, with quality control measures as already described. All demographic and clinical data were anonymized and stored on a central study database (OpenClinica and LabKey). The clinical characteristics of the patients are provided in Supplementary  Tables 1 and 2 . In terms of specifics of sample collection at autopsy, the primary tumor was opened down the midline of the esophagus and the greater curve of the stomach, to expose the lumen. The tumor was divided in 12 areas with sampling as shown. The size of tumors varied per patient, but the division of sampling was always kept identical to preserve reproducibility. In terms of the strategy for genomic sequencing (as per Fig. 1 ), up to three lymph nodes were chosen for 50× WGS in the areas shown (cervical, regional and para-aortic) and up to 24 lymph nodes in each patient (eight further lymph nodes per cervical, regional and paraaortic area (as per the Japanese classification of nodal staging 51 )) were chosen for the 1× WGS part of the study. At least one metastasis per solid organ was chosen for 50× WGS, while for the 1× WGS part, up to eight samples were taken per organ for further analysis. In addition, eight samples from metastatic sites that had previously been sequenced for 50× WGS were further sequenced for 1× WGS, to assess the effects of metastatic heterogeneity.
WGS and data analysis strategy. We used an Illumina HiSeq platform to perform WGS on multiple regions collected from each primary tumor, lymph node and/ or solid organ metastasis (Fig. 1a,b and Supplementary Tables 3 and 4 ). All DNA extractions and WGS conformed to ICGC quality control standards and required ≥70% cellularity and a matched germline sample. WGS was performed at high depth (median coverage: 66.3; IQR: 56.1-87.2) to discover mutations in 122 samples from 18 patients (Supplementary Tables 3 and 4 ). In addition, low-depth WGS (median coverage: 1; IQR: 1-5) was performed to track these mutations spatially in up to 48 solid tissue samples per patient (total = 248) and eight ctDNA samples at autopsy. Temporal tracking was performed in patients with archival biopsy material, and where historical bloods were available ( Supplementary Table 12 , Fig. 5 and Extended Data Fig. 6 ). For each patient, the number of subclones and the CCF within each subclone were inferred using an extension of a previously described Bayesian Dirichlet process 11 , and we applied a set of previously described rules to derive a phylogenetic tree (see additional methods in ref. 52 ). All sequencing data were deposited in the European Genome-phenome Archive under accession number EGAD00001005434. TP53 analysis in ctDNA was performed using Digital PCR on the Bio-Rad platform (Bio-Rad) using validated TP53 assays ( Supplementary Table 14 ).
Mutation clustering and phylogenetic tree construction. The workflow used to perform mutation clustering and phylogenetic tree construction is depicted in Extended Data Fig. 1a and illustrated (with an example patient, S3) in Extended Data Fig. 1b . For each patient, we inferred the number of subclones and the fraction of tumor cells within each subclone using a previously described Bayesian Dirichlet process to cluster mutations according to their mutation copy number 49 . We extended this process into n dimensions for patients with n related samples, where the numbers of mutant reads obtained from multiple related samples were modeled as independent binomial distributions. The Bayesian Dirichlet process uses Markov chain Monte Carlo (MCMC) methods to sample the CCF values of the subclones in each sample. This method (MCMC) is run for 1,000 iterations and outputs, and for each iteration, the sampled position of each cluster, pi h and the weight of each cluster, V h , which is an estimate of the proportion of mutations assigned to that cluster. The first 200 iterations are considered as 'burn-in' and are not used in subsequent steps. To obtain the set of subclones present within a tumor and their CCF values, the following procedure was followed:
• Using the aforementioned MCMC sampling of CCF values from all n samples, for every possible triplet of samples, we obtained posterior density estimates of CCF using the function kde in the R package ks, with input parameters x = pi h , bandwidth = 0.1 and w = V h . We set the grid size such that density estimates were obtained to a resolution of 0.02. Local peaks were identified in the posterior mutation density as locations higher than any other grid point within a range of two grid points. For each local peak, we defined a region representing a 'basin of attraction' , defined by a set of planes running through the point of minimum density between each pair of cluster positions. We assigned each mutation to the cluster in whose basin of attraction it was most likely to fall, using CCF values from MCMC sampling. • Across the set of all possible triplets, we identified sets of mutations that were assigned to the same cluster in every triplet. The CCF of each cluster was estimated as the mean CCF of the mutations assigned to that cluster. We then estimated the 95% confidence intervals as the 0.025-0.975 quantiles of the mean pi h values of the mutations assigned to each cluster within MCMC sampling. • Finally, again using the aforementioned MCMC sampling of CCF values from all n samples, for every pair of samples, we plotted the mutation density, which was estimated using the function kde in the R package ks, with input parameters x = pi h , bandwidth = 0.1 and w = V h .
Taking a conservative approach, clusters were identified as subclonal only if the 95% confidence intervals of the posterior estimate of the proportion of cells excluded the value 1. Clusters containing <1% of all mutations identified in a tumor were not included in phylogenetic reconstruction.
Occasionally, copy number states are incorrectly called in small regions of some cancer genomes. As a consequence, mutations falling in these regions have inaccurate estimates of CCF and can cause artefact clusters. Such clusters may be identified after mutation clustering since they contain a small percentage of mutations (<2.5%), the mutations within them are located in localized regions of the genome and, often, they cannot be placed on the phylogenetic tree because they have discordant CCF values. We excluded these clusters from phylogenetic tree construction. The number of clusters excluded in total was seven (five in P2, one in P3 and one in P10). Two samples had low tumor content (36% in P3_E1 and 14% in S5_T1). As a result, CCF estimates for subclones found in these samples are imprecise and led to violations of the sum rule (see below). The CCF values of the relevant clusters were manually corrected, to enable them to be placed on the phylogenetic tree, as follows: P3_E1-only cluster adjusted from 1 to 0.85; S5_E1 truncal cluster adjusted from 0.85 to 1.
To determine the most likely phylogenetic tree, we applied two rules, as described previously 52 . Briefly, the 'sum rule' (which is an extension of the pigeonhole principle described in ref. 11 ), asserts that if a subclone A is ancestral to both subclones B and C and if the summed CCFs of B and C exceed the CCF of A in any sample, the relationship between the subclones must be linear. The 'crossing rule' is applied to tree construction from multiple samples. It asserts that if the CCF of B is higher than the CCF of C in sample X and the CCF of B is lower than the CCF of C in sample Y, B and C must be in separate branches of the phylogenetic tree (that is, they are not collinear). For all clonally related samples, the same underlying phylogenetic tree must exist. This exerts much greater stringency to the inferred ordering of subclonal clusters present in more than one sample and defines their position on the phylogenetic tree unequivocally. Note that P9 contains two independent cancers derived from Barrett's esophagus and adenocarcinoma regions. CCF values are reported relative to the dominant cancer, so in P9_D4, which contains both cancers, the two cancers are reported with CCFs of 100 and 69%. This apparent violation of the sum rule results from the mathematical convenience of normalizing to the dominant cancer.
It should be noted that the sum rule and crossing rule only strictly apply when the infinite sites assumption is obeyed. The infinite sites assumption states that each mutation only occurs once during the lifetime of a tumor and that mutations never revert to normal. A recent study 53 has shown, through analysis of targeted sequencing of single cells, that the infinite sites assumption is not always followed in real data, for two reasons:
• CNAs (specifically losses and loss of heterozygosity) have the effect of removing mutations in the deleted region, resulting in the apparent 'reversion' of a mutation. • The same mutation may occur on more than one occasion, particularly if the mutation is a driver mutation.
In our study, we take account of CNAs when calculating the CCF of each mutation. In regions that have undergone gain of one or both alleles, a mutation may be present on more than one chromosome copy, up to the number of copies of the most amplified chromosome copy. Conversely, if one or both chromosome copies have undergone loss in a particular sample, a mutation may be lost in that sample. In the situation where a mutation is unobserved in a sample and that sample has a copy number state lower than that observed in another sample in which the mutation is observed, we do not call the mutation as absent. Rather, we cluster it based on its CCF in the remaining samples, treating its CCF in the target sample as unknown.
Identification of CCF.
For each mutation, we calculated the mutation copy number as previously described, using the mutant allele burden, tumor cellularity and locus specific copy number in the tumor and matched normal 49 . The mutation copy number reflects the percentage of tumor cells within a sample carrying that mutation, and permits the cross-comparison of the mutation in related samples despite differences in tumor purity and/or copy number profiles. Mutations present on multiple copies of a chromosomal segment will have a mutation copy number greater than 1. To group mutations according to the percentage of cells containing it, or CCF, the number of chromosomes carrying the mutation must be determined. For all mutations within amplified regions with a major allele copy number, the observed fraction of mutated reads was compared with the expected fraction of mutated reads resulting from a mutation present, assuming a binomial distribution 37 .
Annotation of the trees with mutations. We annotated each tree with oncogenic or putative oncogenic alterations, including substitutions and copy number changes. For substitutions, cluster assignment information from a multidimensional Dirichlet process was used.
For rearrangements and copy number changes, branch assignment was achieved by considering the set of samples containing the variant and the subclonal fraction of the associated copy number segment where applicable. All potential driver alterations were annotated. For substitutions, structural variants and copy number events, these included a set of genes compiled from the TARGET database from the Broad Institute and multiple sequencing datasets for EAC [14] [15] [16] 18, 19 .
Shallow WGS for subclone identification. For shallow WGS, samples were sequenced to a median depth of ~1×. It was not therefore feasible to call mutations de novo for these samples, but we were able to count the number of mutations from each subclone that reported a mutant read in 1× WGS sequencing. We performed simulations of 1× WGS data in order to ascertain the correlation between the number of mutations identified and the CCF of each subclone. First, we simulated subclones with CCF values between 0.01 and 1.00, assuming 1,000 mutations per subclone, a sequencing depth drawn from a Poisson distribution with an expected value 1, and binomial sampling of wild-type and mutant reads. The correlation between the number of mutations detected and the CCF of the subclone was very high (Pearson's r = 0.992; Extended Data Fig. 4 ). To test whether subclones containing fewer mutations also had good correlations between CCF and the number of detected mutations, we performed further simulations of subclones containing between 50 and 1,000 mutations and ascertained that the correlation remained very high (>0.997) for cluster sizes as small as 200 (Extended Data Fig. 5 ). Of the 169 subclones identified in our study, only two contained fewer than 200 mutations, indicating that the number of mutations detected is a good proxy for the CCF of a subclone.
SNVs from libraries sequenced to a minimum of 1× following filtering were allocated to subclones previously identified at 50× WGS. A mapping quality and a base quality of ten were used. This resulted in tabulated counts for SNVs being allocated to subclones identified at 50× WGS for each sample. Normalization was performed according to the number of SNVs assigned to each subclone from 50× WGS, and to the total number of SNVs in that sample, to account for potential differences in coverage, using the following equation: Fig. 2 | Phylogenetic tree construction for example case S3. 1) Battenberg algorithm to determine total copy number (purple line) and minor allele (blue line). Y-axis =number of chromosome copies, X-axis= chromosome and position. The average ploidy, aberrant cell fraction (cellularity) and goodness of fit to the model are shown for each sample, Primary E1, E2, Lymph node L1 and Distant metastasis D1. The goodness of fit is a measure of the amount of the genome with clonal, rather than subclonal copy number states. D1 has a subclonal mix of different copy number states resulting in noninteger total copy number, for example on chromosome 2, resulting in a goodness of fit below 100%. 2) Bayesian Dirichlet Process to cluster SNVs based on CCF in each sample. The density plots show the posterior probability of a mutational cluster, these are produced for every pair of samples and selected plots are shown High density at CCF of (0,0) indicates subclones that are not present in the pair of samples shown in a particular plot. 3) Clustering of results-Clusters are identified as local maxima in the posterior density. The table shows the number of SNVs assigned to each cluster, and their associated CCFs. 4) Unscaled Tree construction using the sum rule and crossing rule as detailed in Supplementary Methods p25. 5) Final Tree -The tree is drawn as seen in Fig. 2 and Extended Data2, branch lengths are proportional to the number of SNVs assigned to each subclone. Scales vary on a per case basis depending on the total number of SNVs, in order to fit cases on one figure. Trees are annotated with the gene names of known drivers, and the colour of each branch represents a trunk (pink), branch (purple) or leaf (yellow). The grey circles represent clones and subclones and their CCFs are shown in Supplementary Table 5 Corresponding author(s): Rebecca Fitzgerald and David Wedge Last updated by author(s): 13.11.2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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